David H. Vesole

12.0k total citations · 1 hit paper
53 papers, 2.0k citations indexed

About

David H. Vesole is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, David H. Vesole has authored 53 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hematology, 29 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in David H. Vesole's work include Multiple Myeloma Research and Treatments (42 papers), Cancer Treatment and Pharmacology (18 papers) and Protein Degradation and Inhibitors (18 papers). David H. Vesole is often cited by papers focused on Multiple Myeloma Research and Treatments (42 papers), Cancer Treatment and Pharmacology (18 papers) and Protein Degradation and Inhibitors (18 papers). David H. Vesole collaborates with scholars based in United States, Canada and France. David H. Vesole's co-authors include Philip R. Greipp, S. Vincent Rajkumar, Rafaël Fonseca, Emily Blood, Mark F. Stinski, Cheryl L. Malone, Sundar Jagannath, Susanna Jacobus, David S. Siegel and Martin M. Oken and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

David H. Vesole

50 papers receiving 1.9k citations

Hit Papers

Phase III Clinical Trial ... 2005 2026 2012 2019 2005 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
    2005 637 citations Emily Blood, David H. Vesole et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David H. Vesole United States 21 1.5k 1.2k 819 270 248 53 2.0k
Cecilie Blimark Sweden 15 1.1k 0.7× 553 0.5× 530 0.6× 187 0.7× 100 0.4× 39 1.5k
Lilian Reich United States 25 1.3k 0.9× 387 0.3× 585 0.7× 553 2.0× 103 0.4× 50 2.2k
Naoki Takezako Japan 21 1.2k 0.8× 734 0.6× 843 1.0× 356 1.3× 199 0.8× 104 1.8k
Ibrahim Aldoss United States 29 1.1k 0.8× 550 0.5× 899 1.1× 251 0.9× 250 1.0× 190 2.5k
Hellmut Ottinger Germany 21 987 0.7× 106 0.1× 330 0.4× 834 3.1× 289 1.2× 49 1.6k
T. Klingebiel Germany 21 599 0.4× 428 0.4× 467 0.6× 249 0.9× 544 2.2× 62 1.9k
Yener Koç Türkiye 22 1.1k 0.8× 132 0.1× 566 0.7× 429 1.6× 250 1.0× 84 1.8k
Woo-Sung Min South Korea 21 1.2k 0.8× 228 0.2× 435 0.5× 454 1.7× 284 1.1× 131 1.7k
J Pris France 22 571 0.4× 243 0.2× 424 0.5× 170 0.6× 113 0.5× 79 1.3k
Emmanuelle Tavernier France 18 840 0.6× 326 0.3× 330 0.4× 104 0.4× 74 0.3× 73 1.4k

Countries citing papers authored by David H. Vesole

Since Specialization
Citations

This map shows the geographic impact of David H. Vesole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Vesole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Vesole more than expected).

Fields of papers citing papers by David H. Vesole

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Vesole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Vesole. The network helps show where David H. Vesole may publish in the future.

Co-authorship network of co-authors of David H. Vesole

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Vesole. A scholar is included among the top collaborators of David H. Vesole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Vesole. David H. Vesole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kabat, Maciej, Andrew Ip, Hyung C. Suh, et al.. (2025). Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia. Transplantation and Cellular Therapy. 31(12). 1010–1019.
2.
Jurczyszyn, Artur, et al.. (2025). New therapies in multiple myeloma: benefits and limitations. Polskie Archiwum Medycyny Wewnętrznej. 135(4). 1 indexed citations
3.
Lesokhin, Alexander M., Rubén Niesvizky, Bertrand Arnulf, et al.. (2025). Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3. Blood. 146(Supplement 1). 2269–2269.
4.
5.
6.
Manier, Salomon, Alexander M. Lesokhin, Mohamad Mohty, et al.. (2023). P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES. HemaSphere. 7(S3). e26808c7–e26808c7. 3 indexed citations
7.
Stewart, A. Keith, Andrzej Jakubowiak, Sundar Jagannath, et al.. (2011). The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study.. Journal of Clinical Oncology. 29(15_suppl). 8026–8026. 5 indexed citations
8.
Jakubowiak, Andrzej, Dominik Dytfeld, Sundar Jagannath, et al.. (2011). Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). Blood. 118(21). 631–631. 18 indexed citations
9.
Jakubowiak, Andrzej, Dominik Dytfeld, Sundar Jagannath, et al.. (2010). Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. Blood. 116(21). 862–862. 12 indexed citations
10.
Bensinger, William, Sundar Jagannath, Robert Vescio, et al.. (2009). Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. British Journal of Haematology. 148(4). 562–568. 19 indexed citations
11.
Bensinger, William, Sundar Jagannath, Robert Vescio, et al.. (2008). A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma. Blood. 112(11). 94–94. 20 indexed citations
12.
13.
Vesole, David H.. (2007). Bone marrow and stem cell transplantation for multiple myeloma. Cancer treatment and research. 99. 171–194.
14.
Kukreja, Anjli, Amitabha Mazumder, David H. Vesole, et al.. (2006). Bortezomib disrupts tumour–dendritic cell interactions in myeloma and lymphoma: therapeutic implications. British Journal of Haematology. 136(1). 106–110. 28 indexed citations
15.
Dispenzieri, Angela, Emily Blood, David H. Vesole, et al.. (2005). A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).. Blood. 106(11). 2546–2546. 4 indexed citations
16.
Vesole, David H., et al.. (2003). Management of renal dysfunction in multiple myeloma. Current Treatment Options in Oncology. 4(3). 239–246. 10 indexed citations
17.
Keever-Taylor, Carolyn A., Christopher Bredeson, Fausto R. Loberiza, et al.. (2001). Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biology of Blood and Marrow Transplantation. 7(11). 620–630. 51 indexed citations
18.
Vesole, David H., et al.. (1999). Acute tumour lysis syndrome: a case in AL amyloidosis. British Journal of Haematology. 107(2). 386–387. 4 indexed citations
19.
Barlogie, Bart, Kenneth C. Anderson, James R. Berenson, et al.. (1995). Transplants for multiple myeloma. 15(1). 10 indexed citations
20.
Vesole, David H., Jean‐Michel Goust, James W. Fett, Philippe Arnaúd, & H. Hugh Fudenberg. (1979). An inhibitor of DNA synthesis produced by established lymphoid cell lines. Clinical Immunology and Immunopathology. 14(4). 489–501. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cecilie Blimark Breakdown of academic impact, for papers by Lilian Reich Breakdown of academic impact, for papers by Naoki Takezako Breakdown of academic impact, for papers by Ibrahim Aldoss Breakdown of academic impact, for papers by Hellmut Ottinger Breakdown of academic impact, for papers by T. Klingebiel Breakdown of academic impact, for papers by Yener Koç Breakdown of academic impact, for papers by Woo-Sung Min Breakdown of academic impact, for papers by J Pris Breakdown of academic impact, for papers by Emmanuelle Tavernier
Rankless by CCL
2026